← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV20행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))
TransMolecular·CD19
60 trials
Overview
Program
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
Overview
Company
TransMolecular
Overview
Modality
CGT
Overview
Target
CD19
Overview
Indication
Recurrent Glioblastoma; Recurrent Malignant Glioma
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Biomarker
biomarker of systemic nicotine absorption
PK/PD
Species
Pig
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Pig
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
Clinical, procedural and patient-reported outcomes of the Ultimaster Nagomi sirolimus-eluting coronary stent in complex percutaneous coronary intervention: the NAGOMI COMPLEX prospective cohort study protocol.. Percutaneous coronary intervention (PCI) has evolved significantly over the past decade with approximately 30% of patients presenting with complex coronary artery disease, posing heightened…
Clinical
Safety signal
Clinical, procedural and patient-reported outcomes of the Ultimaster Nagomi sirolimus-eluting coronary stent in complex percutaneous coronary intervention: the NAGOMI COMPLEX prospective cohort study protocol.. Percutaneous coronary intervention (PCI) has evolved significantly over the past decade with approximately 30% of patients presenting with complex coronary artery disease, posing heightened…
Clinical
Program phase
PHASE_1